Since they were first reported in 1975, monoclonal antibodies have developed from tools in basic research, to diagnostic agents, and more recently, with humanization, to the status of bona fide therapeutic agents. Nature Biotechnology, Nature Medicine and Nature Cell Biology present a focus on monoclonal antibodies, covering basic, technological and clinical aspects of their use, and stretching across fields that range from transplantation tolerance to colon cancer.

The variety of articles presented is designed to reflect the diverse content of these three journals. The importance and breadth of monoclonal antibody applications is reflected in the fact that this reagent surfaces frequently throughout the Nature family of journals – gratifyingly, with ever-increasing frequency in the clinical arena. More examples of recent research papers where monoclonal antibodies have a central role can be found in the "Nature Journals' Selection" section of this website; selected articles are free for a period of six months.



Monoclonal Antibodies and Therapies



Erbitux diagnostic latest adjunct to cancer therapy

Peter Mitchell

Nature Biotechnology 22, 363-364 (2004)

EGFR inhibitors square off at ASCO

Monya Baker

Nature Biotechnology 22, 641-641 (2004)



Signal transduction inhibitors—a work in progress

Joseph Becker

Nature Biotechnology 22, 15-18 (2004)



Hsp90 invades the outside

Didier Picard

Nature Cell Biology 6, 479-480 (2004)



Engineered antibodies

Peter J. Hudson & Christelle Souriau

Nature Medicine 9, 129-134 (2003)

Immunotherapy: past, present and future

Thomas A. Waldmann

Nature Medicine 9, 269-277 (2003)



Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. Chen, Paul C. Shellito, Gregory Y. Lauwers & Rakesh K. Jain

Nature Medicine 10, 145-147 (2004)

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

Peter M. Smith-Jones, David B. Solit, Timothy Akhurst, Farzana Afroze, Neal Rosen & Steven M. Larson

Nature Biotechnology 22, 701-706 (2004)

Analyzing antibody specificity with whole proteome microarrays

Gregory A. Michaud, Michael Salcius, Fang Zhou, Rhonda Bangham, Jaclyn Bonin, Hong Guo, Michael Snyder, Paul F. Predki & Barry I. Schweitzer

Nature Biotechnology 21, 1509-1512 (2003)

Fingerprinting the circulating repertoire of antibodies from cancer patients

Paul J. Mintz, Jeri Kim, Kim-Anh Do, Xuemei Wang, Ralph G. Zinner, Massimo Cristofanilli, Marco A. Arap, Waun Ki Hong, Patricia Troncoso, Christopher J. Logothetis, Renata Pasqualini & Wadih Arap

Nature Biotechnology 21, 57-63 (2002)

Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness

Brenda K. Eustace, Takashi Sakurai, Jean K. Stewart, Dean Yimlamai, Christine Unger, Carol Zehetmeier, Blanca Lain, Claudia Torella, Stefan W. Henning, Gerald Beste, Bradley T. Scroggins, Len Neckers, Leodevico L. Ilag & Daniel G. Jay

Nature Cell Biology 6, 507-514 (2004)

Telomerase modulates expression of growth-controlling genes and enhances cell proliferation

Laura L. Smith, Hilary A. Coller & James M. Roberts

Nature Cell Biology 5, 474-479 (2003)

Extra navigation